Causal Inference of CLEC5A and ISG20 in Atherosclerosis: Integrating Genetic and Functional Evidence

Study Background and Research Question

Atherosclerosis (AS) remains a leading cause of cardiovascular morbidity and mortality worldwide, fundamentally driven by lipid accumulation and chronic inflammation in the arterial wall. Although immune and genetic factors have long been implicated in atherosclerosis, the precise molecular regulators and their causal roles are incompletely defined. Recent advances in genomics and high-throughput transcriptomics have enabled a more systematic interrogation of candidate genes, yet bridging association to causality continues to challenge the field. The study by Zhang et al. (2025) directly addresses this gap by integrating Mendelian randomization (MR) and expression quantitative trait locus (eQTL) analysis to identify and validate causal regulators of AS, with a focus on the genes CLEC5A and ISG20 (Zhang et al., 2025).

Key Innovation from the Reference Study

The principal innovation lies in the combined use of large-scale transcriptomic datasets, genetic association tools, and experimental validation to move beyond correlation and establish causality for key immune regulators in AS. While previous studies have catalogued differential gene expression in atherosclerotic lesions, Zhang et al. demonstrate, through two-sample MR and eQTL colocalization, that upregulation of CLEC5A and ISG20 is not merely a consequence of disease but likely plays a direct pathogenic role. This integrated approach strengthens the evidence for these genes as actionable drivers of atherogenesis and sets a new methodological standard for mechanistic discovery in vascular immunology.

Methods and Experimental Design Insights

The authors combined data from the Gene Expression Omnibus (GEO) with eQTL analysis to identify genes whose expression is both altered in AS and under genetic control. Mendelian randomization was used to infer directionality and causal inference between gene expression and disease risk. The study prioritized genes with strong MR evidence and further examined their biological functions through enrichment analysis. For experimental validation, the upregulation of ISG20 was confirmed using RT-qPCR and Western blot in both oxidized LDL-treated macrophages and atherosclerotic plaques from ApoE–/– mice. Immunofluorescence co-staining and immunohistochemistry were employed to localize ISG20 in endothelial and macrophage-rich regions of atherosclerotic lesions, leveraging immunohistochemistry secondary antibodies for robust detection (Zhang et al., 2025).

Protocol Parameters

• Gene Selection: Differentially expressed genes identified from GEO datasets were cross-referenced with eQTL data to prioritize candidates with genetically regulated expression patterns.
• Mendelian Randomization: Two-sample MR was performed using summary statistics from genome-wide association studies and eQTL data to determine causal effects on AS risk.
• Experimental Validation: Macrophages were stimulated with oxidized LDL to model foam cell formation, followed by RT-qPCR and Western blot for gene expression analysis.
• Immunofluorescence and IHC: Localization of ISG20 in tissue sections was performed using immunohistochemistry and immunocytochemistry (ICC/IF) protocols with rabbit primary antibodies and appropriate goat anti-rabbit IgG secondary antibodies conjugated to fluorophores.
• Statistical Analysis: Differential expression and causality were assessed using appropriate statistical models, with significance thresholds set at P < 0.05.

Core Findings and Why They Matter

CLEC5A and ISG20 were found to be significantly upregulated in human and murine models of atherosclerosis. MR analysis established positive causal relationships between the expression of these genes and AS risk (odds ratio for both ≈1.001, P<0.05), while HOXA2 showed a negative association. Functional enrichment revealed their central involvement in immune responses, inflammatory signaling, and lipid metabolism. Notably, ISG20 expression was markedly increased in macrophage- and endothelial-rich regions of plaques, as confirmed by immunofluorescence and immunohistochemistry. These findings suggest that ISG20 contributes to AS progression through modulation of macrophage lipid accumulation and inflammatory programs, positioning it as a promising therapeutic target (Zhang et al., 2025).

This mechanistic clarity is particularly valuable, as it bridges the gap between genetic association and functional relevance, offering a new axis for intervention in AS beyond traditional lipid-lowering strategies.

Comparison with Existing Internal Articles

The current findings harmonize with recent internal resources that emphasize the importance of high-specificity immunodetection in unraveling atherosclerotic mechanisms. For example, the article "Illuminating Atherosclerosis Mechanisms: Strategic Multiplexing" highlights the necessity of multiplexed protein detection to dissect immune and genetic interactions in AS. Similarly, "Precision in Immune Pathway Discovery" discusses how advanced immunohistochemistry secondary antibodies, such as goat anti-rabbit IgG reagents, are foundational for reliable detection of immune markers in vascular lesions. Zhang et al.'s approach, which relies on robust immunofluorescence and IHC protocols, underscores the practical relevance of these technical advances for validating new molecular targets.

Furthermore, the utility of fluorophore-conjugated secondary antibodies with defined excitation and emission spectra is echoed in resources detailing practical workflow optimization for immunocytochemistry (ICC/IF) and flow cytometry (FC) in translational cardiovascular research.

Limitations and Transferability

While the study by Zhang et al. offers compelling evidence for the causal involvement of CLEC5A and ISG20 in AS, several limitations warrant consideration. The MR approach is contingent on the quality and completeness of GWAS and eQTL datasets, and potential horizontal pleiotropy may confound causal inference despite statistical controls. Experimental validation, although robust in mouse and cell models, may not fully recapitulate the complexity of human disease, particularly with respect to tissue-specific regulatory mechanisms and environmental factors. Therefore, while the evidence for ISG20 as a therapeutic target is strong, further translational studies are required to assess its druggability and safety in clinical contexts.

The methods described are highly transferable for the study of other immune-driven vascular diseases, provided that genetic and transcriptomic resources are available. However, workflow reproducibility relies on the consistent use of validated antibodies and detection reagents in immunohistochemistry and related assays.

Research Support Resources

Researchers aiming to replicate or extend these findings can leverage high-quality detection reagents for immunocytochemistry, immunohistochemistry, and flow cytometry workflows. For example, the HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody (SKU K3305) from APExBIO is designed for sensitive and specific detection of rabbit primary antibodies, supporting fluorescence-based multiplexing in ICC/IF, IHC, and FC protocols. This reagent, with a defined excitation maximum at 590 nm and emission at 617 nm, ensures robust signal detection and compatibility with common filter sets, as described in its product information. Using such validated tools can enhance assay reproducibility and support the rigorous localization of immune markers like ISG20 in experimental atherosclerosis models.